×

AMAG Pharmaceuticals, Inc. to Host Conference Call on July 23, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Three and Six Months Ended June 30, 2015

WALTHAM, Mass., July 17, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the three and six months ended June 30, 2015 before the U.S. financial markets open on Thursday, July 23, 2015. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will discuss the company's second quarter financial results and provide an update on business matters, commercial performance, regulatory status, and business development activities, including the pending acquisition of Cord Blood Registry.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on July 23, 2015 through midnight on July 30, 2015. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 81280898.

The call will be webcast with slides and accessible through the Investors section of the company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:00a.m. ET on July 23, 2015 through midnight August 21, 2015.

About AMAG

As a high-growth specialty pharmaceutical company, AMAG Pharmaceuticals uses its business and clinical expertise to bring medical therapies and other innovations to market that provide clear benefits and improve people's lives. Based in Waltham, Mass., AMAG has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its aggressive growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG's existing therapeutic areas or those that could benefit from its proven core competencies. For additional company information, please visit www.amagpharma.com.

CONTACT: AMAG Pharmaceuticals, Inc. Contact: Linda Lennox Vice President, Investor Relations & Corporate Communications 617-498-2846

Source:AMAG Pharmaceuticals, Inc.